During 2021, following analysis of the preliminary pharmacokinetic (“PK”) data from our Phase I MAD clinical trial, Liminal announced that the Company would not be progressing the development of fezagepras for the treatment of idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia.

Since that announcement, the Company has completed the clinical phase of the Phase I MAD clinical trial and continues to analyse the resulting data. In addition, the Company is continuing to perform additional pre-clinical research and is preparing to perform additional early clinical research on fezagepras with a view toward determining any potential new indications. The Company expects to provide an update on the outcome of this additional research in the first half of 2022.